The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Sydney cancer immunotherapy research company, Imugene has presented positive vaccine trial results at the Annual American Association for Cancer Research. The results were released after a trial period on a genetically identical mouse-model subject with HER-2+ breast cancer. B-cell cancer growth was inhibited in the test subject after implementation of the newly developed mimitope programmed cell death protein (PD-1). The PD-1 elicited an antibody response in the mouse that inhibited growth of the cancer tumor. Imugene collaborated with the Medical University of Vienna at the Annual American during the trial tests. Please read the announcement attached.
IMU by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…